Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathelijne H van der Wouden

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Genes|June 1, 2019
Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World ImpactCathelijne H van der Wouden, Paul C D Bank, Kübra Özokcu, et al.
Frontiers in Pharmacology|September 19, 2022
Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic ModelCathelijne H van der Wouden, Heiralde Marck, Henk-Jan Guchelaar, et al.
Journal of Clinical Medicine|March 21, 2020
Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical FrameworkCathelijne H van der Wouden, Ellen Paasman, Martina Teichert, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 23, 2016
Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) StudyDeanna Alexis Carere, Tyler J VanderWeele, Jason L Vassy, et al.
Annals of Internal Medicine|March 2, 2016
Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic TestingCathelijne H van der Wouden, Deanna Alexis Carere, Anke H Maitland-van der Zee, et al.
Clinical Pharmacology and Therapeutics|May 1, 2019
Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic TestingCathelijne H van der Wouden, Mandy H van Rhenen, Wafa O M Jama, et al.
Journal of the American Medical Informatics Association : JAMIA|February 15, 2018
Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) projectKathrin Blagec, Rudolf Koopmann, Mandy Crommentuijn-van Rhenen, et al.
European Journal of Human Genetics : EJHG|November 21, 2019
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidinesCarin A T C Lunenburg, Cathelijne H van der Wouden, Marga Nijenhuis, et al.
Pharmacogenetics and Genomics|April 23, 2020
Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE studyCathelijne H van der Wouden, Stefan Böhringer, Erika Cecchin, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE StudyHenk-Jan Guchelaar, Cathelijne H van der Wouden, Lisanne E N Manson, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Genes|June 1, 2019
Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World ImpactCathelijne H van der Wouden, Paul C D Bank, Kübra Özokcu, et al.
Frontiers in Pharmacology|September 19, 2022
Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic ModelCathelijne H van der Wouden, Heiralde Marck, Henk-Jan Guchelaar, et al.
Journal of Clinical Medicine|March 21, 2020
Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical FrameworkCathelijne H van der Wouden, Ellen Paasman, Martina Teichert, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 23, 2016
Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) StudyDeanna Alexis Carere, Tyler J VanderWeele, Jason L Vassy, et al.
Annals of Internal Medicine|March 2, 2016
Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic TestingCathelijne H van der Wouden, Deanna Alexis Carere, Anke H Maitland-van der Zee, et al.
Clinical Pharmacology and Therapeutics|May 1, 2019
Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic TestingCathelijne H van der Wouden, Mandy H van Rhenen, Wafa O M Jama, et al.
Journal of the American Medical Informatics Association : JAMIA|February 15, 2018
Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) projectKathrin Blagec, Rudolf Koopmann, Mandy Crommentuijn-van Rhenen, et al.
European Journal of Human Genetics : EJHG|November 21, 2019
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidinesCarin A T C Lunenburg, Cathelijne H van der Wouden, Marga Nijenhuis, et al.
Pharmacogenetics and Genomics|April 23, 2020
Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE studyCathelijne H van der Wouden, Stefan Böhringer, Erika Cecchin, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE StudyHenk-Jan Guchelaar, Cathelijne H van der Wouden, Lisanne E N Manson, et al.
Pageof 2